Will teclistamab be officially included in medical insurance and policy updates in 2025?

As of 2025 July , teritolumab (Teclistamab) has been approved for marketing in China, but has not yet been included in the national medical insurance directory. The drug, developed by Johnson & Johnson, is a drug that targets B cell maturation antigen (BCMA) and T< bispecific antibodies against span>cell surfaceCD3 receptors, mainly used to treat adult patients with relapsed or refractory multiple myeloma (RRMM). Although it has been approved for marketing in Europe and the United States and has been included as a breakthrough therapy in China, patients still need to purchase it at their own expense.

The high price of teritusumab is the main obstacle that prevents it from being included in medical insurance. According to public information, a box of the original research version 153mg/1.7ml is priced at more than 50,000 yuan. Due to its innovation and efficacy, teritusumab is regarded as one of the key drug candidates for future medical insurance negotiations. However, whether it can be successfully included in medical insurance still depends on the profit margin of the enterprise and the cost-effectiveness evaluated by the National Medical Insurance Bureau.

According to relevant reports, teritusumab will be fully included in the medical insurance catalog in 2025 still needs to observe policy dynamics, price negotiation results and market feedback. Considering that China is accelerating its acceptance of innovative drugs and that medical insurance policies are increasingly focusing on clinical value orientation, the medical insurance prospects of this drug deserve long-term attention. Patients and clinicians can pay close attention to the National Medical Insurance Administration’s annual drug negotiation updates to obtain the latest progress information.

Before medical insurance covers it, patients can pay attention to hospital clinical research, charitable drug donation projects or auxiliary reimbursement mechanisms. At the same time, a reasonable treatment plan should be formulated under the guidance of a professional doctor by weighing the efficacy and cost. The medical insurance trends of teritusumab also deserve continued attention from patients and the industry.

Reference materials:https://www.drugs.com/